Argyle Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.26M | Buy |
151,876
+5,950
| +4% | +$158K | 1.39% | 22 |
|
|
2025
Q4 | $3.63M | Buy |
145,926
+8,000
| +6% | +$202K | 1.21% | 29 |
|
|
2025
Q3 | $3.51M | Sell |
137,926
-280
| -0.2% | -$6.91K | 1.22% | 29 |
|
|
2025
Q2 | $3.35M | Sell |
138,206
-500
| -0.4% | -$11.7K | 1.21% | 28 |
|
|
2025
Q1 | $3.51M | Buy |
138,706
+3,900
| +3% | +$102K | 1.31% | 27 |
|
|
2024
Q4 | $3.58M | Buy |
134,806
+7,320
| +6% | +$199K | 1.41% | 22 |
|
|
2024
Q3 | $3.69M | Sell |
127,486
-5,085
| -4% | -$148K | 1.47% | 20 |
|
|
2024
Q2 | $3.71M | Buy |
132,571
+7,725
| +6% | +$213K | 1.53% | 18 |
|
|
2024
Q1 | $3.46M | Buy |
124,846
+7,563
| +6% | +$210K | 1.34% | 25 |
|
|
2023
Q4 | $3.38M | Sell |
117,283
-19,917
| -15% | -$602K | 1.4% | 24 |
|
|
2023
Q3 | $4.55M | Hold |
137,200
| – | – | 1.67% | 13 |
|
|
2023
Q2 | $5.03M | Sell |
137,200
-4,107
| -3% | -$160K | 1.81% | 11 |
|
|
2023
Q1 | $5.77M | Hold |
141,307
| – | – | 2.03% | 8 |
|
|
2022
Q4 | $7.24M | Sell |
141,307
-345
| -0.2% | -$16.5K | 2.49% | 4 |
|
|
2022
Q3 | $6.2M | Buy |
141,652
+200
| +0.1% | +$9.72K | 2.41% | 5 |
|
|
2022
Q2 | $7.42M | Sell |
141,452
-1,254
| -0.9% | -$63.9K | 2.66% | 3 |
|
|
2022
Q1 | $7.39M | Sell |
142,706
-6,491
| -4% | -$337K | 2.4% | 3 |
|
|
2021
Q4 | $8.81M | Sell |
149,197
-2,400
| -2% | -$119K | 2.75% | 2 |
|
|
2021
Q3 | $6.52M | Sell |
151,597
-300
| -0.2% | -$13.3K | 2.16% | 4 |
|
|
2021
Q2 | $5.95M | Hold |
151,897
| – | – | 1.92% | 11 |
|
|
2021
Q1 | $5.5M | Hold |
151,897
| – | – | 1.85% | 8 |
|
|
2020
Q4 | $5.59M | Sell |
151,897
-8,202
| -5% | -$301K | 2.08% | 7 |
|
|
2020
Q3 | $5.58M | Sell |
160,099
-1,687
| -1% | -$59.1K | 2.28% | 5 |
|
|
2020
Q2 | $5.02M | Sell |
161,786
-352
| -0.2% | -$12K | 2.11% | 6 |
|
|
2020
Q1 | $5.02M | Buy |
162,138
+353
| +0.2% | +$12K | 2.37% | 6 |
|
|
2019
Q4 | $6.01M | Sell |
161,785
-421
| -0.3% | -$15K | 2.14% | 8 |
|
|
2019
Q3 | $5.53M | Buy |
162,206
+737
| +0.5% | +$26.8K | 2.09% | 6 |
|
|
2019
Q2 | $6.64M | Buy |
161,469
+422
| +0.3% | +$16.8K | 2.52% | 3 |
|
|
2019
Q1 | $6.49M | Hold |
161,047
| – | – | 2.49% | 4 |
|
|
2018
Q4 | $6.67M | Sell |
161,047
-2,108
| -1% | -$87.5K | 2.82% | 3 |
|
|
2018
Q3 | $6.82M | Sell |
163,155
-307
| -0.2% | -$11.8K | 2.55% | 2 |
|
|
2018
Q2 | $5.63M | Sell |
163,462
-186
| -0.1% | -$6.36K | 2.23% | 5 |
|
|
2018
Q1 | $5.51M | Sell |
163,648
-3,172
| -2% | -$109K | 2.18% | 5 |
|
|
2017
Q4 | $5.73M | Sell |
166,820
-1,159
| -0.7% | -$39.5K | 2.15% | 4 |
|
|
2017
Q3 | $5.69M | Sell |
167,979
-211
| -0.1% | -$6.78K | 2.23% | 5 |
|
|
2017
Q2 | $5.36M | Sell |
168,190
-1,159
| -0.7% | -$36.5K | 2.18% | 3 |
|
|
2017
Q1 | $5.5M | Buy |
169,349
+76
| +0% | +$2.4K | 2.24% | 3 |
|
|
2016
Q4 | $5.22M | Sell |
169,273
-589
| -0.3% | -$18K | 2.22% | 3 |
|
|
2016
Q3 | $5.46M | Sell |
169,862
-3,847
| -2% | -$129K | 2.37% | 3 |
|
|
2016
Q2 | $5.8M | Hold |
173,709
| – | – | 2.46% | 3 |
|
|
2016
Q1 | $4.88M | Buy |
173,709
+1,476
| +0.9% | +$42.2K | 2.22% | 6 |
|
|
2015
Q4 | $5.28M | Sell |
172,233
-3,773
| -2% | -$119K | 2.43% | 3 |
|
|
2015
Q3 | $5.25M | Sell |
176,006
-4,583
| -3% | -$147K | 2.56% | 3 |
|
|
2015
Q2 | $5.75M | Sell |
180,589
-951
| -0.5% | -$31K | 2.63% | 2 |
|
|
2015
Q1 | $5.99M | Sell |
181,540
-1,423
| -0.8% | -$45.2K | 2.68% | 2 |
|
|
2014
Q4 | $5.41M | Hold |
182,963
| – | – | 2.37% | 5 |
|
|
2014
Q3 | $5.13M | Sell |
182,963
-569
| -0.3% | -$16K | 2.36% | 5 |
|
|
2014
Q2 | $5.17M | Buy |
183,532
+8,643
| +5% | +$246K | 2.41% | 3 |
|
|
2014
Q1 | $5.33M | Sell |
174,889
-1,423
| -0.8% | -$42.4K | 2.62% | 3 |
|
|
2013
Q4 | $5.12M | Sell |
176,312
-374
| -0.2% | -$10.9K | 2.58% | 2 |
|
|
2013
Q3 | $4.82M | Sell |
176,686
-1,054
| -0.6% | -$28.7K | 2.64% | 3 |
|
|
2013
Q2 | $4.72M | Buy |
+177,740
| New | +$4.91M | 2.71% | 2 |
|
Other funds holding PFE
VCM
VPM
Argyle Capital Management's PFE Position: Q1 2026 in Review
Argyle Capital Management increased its Pfizer (PFE) stake by 4.1% in Q1 2026, buying an estimated $158K and bringing the position to 151,876 shares worth $4.26M. The position accounts for 1.39% of the portfolio, ranked #22.
Argyle Capital Management first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $8.81M in Q4 2021. 2,935 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Argyle Capital Management held 151,876 shares of Pfizer worth $4.26M as of Q1 2026.
- Argyle Capital Management bought 5,950 Pfizer shares in Q1 2026, an estimated $158K.
- Pfizer made up 1.39% of Argyle Capital Management's portfolio in Q1 2026, its #22 holding.
- Argyle Capital Management first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
- Argyle Capital Management's Pfizer position peaked at $8.81M in Q4 2021.
- 2,935 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Argyle Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.